September, 2016
EC granted € 5M to a consortium in which Blueclinical is responsible for the regulatory plan and early clinical trials
Blueclinical is part of a H2020 Consortium which is working on an innovative approach to treat Rheumatoid Arthritis. It should reach phase I clinical trials in 2018.
